| Wall Street Analysts See a 195.05% Upside in Trevi Therapeutics (TRVI): Can the Stock Really Move This High? |
The mean of analysts' price targets for Trevi Therapeutics (TRVI) points to a 195.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2025-05-14 15:00:59 |
Czytaj oryginał (ang.) |
| Trevi Therapeutics, Inc. (TRVI) Q1 2025 Earnings Call Transcript |
Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Jennifer Good - Co-Founder, President and Chief Executive Officer Lisa Delfini - Chief Financial Officer James Cassella - Chief Development Officer Farrell Simon - Chief Commercial Officer Conference Call Participants Faisal Khurshid - Leerink Annabel Samimy - Stifel Leland Gershell - Oppenheimer Deepa Njama - Jones Trading Mayank Mamtani - B. Riley Securities Kaveri Pohlman - Clear Street Operator Good afternoon and welcome to the Trevi Therapeutics First Quarter 2025 Earnings Conference Call. |
seekingalpha.com |
2025-05-11 08:16:32 |
Czytaj oryginał (ang.) |
| Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates |
Completed enrollment and last patient last visit in the Phase 2b CORAL trial in IPF patients with chronic cough; topline results continue to be expected in the second quarter of 2025 Announced positive topline results from the Phase 2a RIVER trial in patients with refractory chronic cough Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn. |
prnewswire.com |
2025-05-08 20:05:00 |
Czytaj oryginał (ang.) |
| Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025 |
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn. |
prnewswire.com |
2025-05-01 20:05:00 |
Czytaj oryginał (ang.) |
| Trevi Therapeutics to Participate in Upcoming April Investor Conferences |
NEW HAVEN, Conn. , April 3, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be participating in the following investor conferences in April. |
prnewswire.com |
2025-04-03 11:30:00 |
Czytaj oryginał (ang.) |
| Trevi Therapeutics, Inc. (TRVI) Q4 2024 Earnings Call Transcript |
Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ET Company Participants Jennifer Good - Co-Founder, President and Chief Executive Officer Lisa Delfini - Chief Financial Officer Conference Call Participants Faisal Khurshid - Leerink Partners Mayank Mamtani - B. Riley Annabel Samimy - Stifel Leland Gershell - Oppenheimer Serge Belanger - Needham & Company Ryan Deschner - Raymond James Brandon Folkes - Rodman & Renshaw Christian Cubides - Clear Street Operator Good afternoon and welcome to the Trevi Therapeutics Fourth Quarter and Year End 2024 Earnings Conference Call. |
seekingalpha.com |
2025-03-18 20:47:38 |
Czytaj oryginał (ang.) |
| Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates |
Announced positive topline data from the Phase 2a RIVER trial in patients with refractory chronic cough (RCC), making Haduvio the first therapy in clinical development to show benefit in patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and RCC Completed enrollment in the Phase 2b CORAL trial in IPF patients with chronic cough in February 2025, with topline data expected in the second quarter of 2025 Announced positive outcome from sample size re-estimation in the Phase 2b CORAL trial, resulting in no change to study sample size Ended 2024 with $107.6 million in cash, cash equivalents and marketable securities, with expected cash runway into the second half of 2026 Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn. |
prnewswire.com |
2025-03-18 18:05:00 |
Czytaj oryginał (ang.) |
| Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025 |
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn. |
prnewswire.com |
2025-03-11 18:05:00 |
Czytaj oryginał (ang.) |
| Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps |
On Monday, Trevi Therapeutics, Inc. TRVI reported topline results from its Phase 2a RIVER trial of Haduvio (oral nalbuphine ER) for the treatment of patients with refractory chronic cough (N=66). |
benzinga.com |
2025-03-10 13:30:31 |
Czytaj oryginał (ang.) |
| Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough |
Haduvio met the primary endpoint with a statistically-significant reduction (p |
prnewswire.com |
2025-03-10 08:00:00 |
Czytaj oryginał (ang.) |
| Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough |
Conference call and webcast to be held at 8:30 a.m. ET NEW HAVEN, Conn. |
prnewswire.com |
2025-03-09 18:00:00 |
Czytaj oryginał (ang.) |
| Trevi Therapeutics to Participate in Upcoming March Investor Conferences |
NEW HAVEN, Conn. , Feb. 27, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending the following investor conferences in March. |
prnewswire.com |
2025-02-27 09:30:00 |
Czytaj oryginał (ang.) |
| Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough |
Topline results continue to be expected in the first half of 2025 NEW HAVEN, Conn. , Feb. 25, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that it has completed enrollment in its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF. |
prnewswire.com |
2025-02-25 09:30:00 |
Czytaj oryginał (ang.) |
| Trevi Therapeutics to Participate in Upcoming February Investor Conferences |
NEW HAVEN, Conn. , Jan. 30, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending the following investor conferences in February. |
prnewswire.com |
2025-01-30 09:30:00 |
Czytaj oryginał (ang.) |
| What Makes Trevi Therapeutics (TRVI) a New Buy Stock |
Trevi Therapeutics (TRVI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-01-08 15:00:49 |
Czytaj oryginał (ang.) |
| Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference |
Last patient completed the Phase 2a RIVER trial in refractory chronic cough (RCC) in early January and topline results continue to be expected in the first quarter of 2025 Approximately 80% of enrollment complete in the Phase 2b CORAL trial in idiopathic pulmonary fibrosis (IPF) patients with chronic cough and topline results continue to be expected in the first half of 2025 NEW HAVEN, Conn. , Jan. 8, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced business updates ahead of its participation in the 14th Annual LifeSci Partners Corporate Access Event taking place in San Francisco, CA, from January 13-15, 2025. |
prnewswire.com |
2025-01-08 09:30:00 |
Czytaj oryginał (ang.) |
| Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering |
NEW HAVEN, Conn. , Dec. 16, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy, Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at a price to investors of $4.00 per share, for total proceeds of $50 million, before deducting underwriting discounts and commissions and expenses payable by Trevi. |
prnewswire.com |
2024-12-16 09:36:00 |
Czytaj oryginał (ang.) |
| Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday? |
On Thursday, Trevi Therapeutics, Inc. TRVI announced the outcome from the planned sample size re-estimation (SSRE) for the ongoing Phase 2b CORAL trial in idiopathic pulmonary fibrosis (IPF) patients with chronic cough, which requires no change to the current sample size for the trial (N=160). |
benzinga.com |
2024-12-12 11:47:23 |
Czytaj oryginał (ang.) |
| Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough |
Independent Data Monitoring Statistician reaffirmed current sample size to remain at N=160 The trial has reached 75% of the targeted enrollment, and topline results continue to be expected in the first half of 2025 NEW HAVEN, Conn. , Dec. 12, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the positive outcome from the planned sample size re-estimation (SSRE) for the ongoing Phase 2b CORAL trial in IPF patients with chronic cough, which requires no change to the current sample size for the trial (N=160). |
prnewswire.com |
2024-12-12 09:30:00 |
Czytaj oryginał (ang.) |
| Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine |
Statistically significant lower "Drug Liking" for the 81mg and 162mg doses of oral nalbuphine vs. butorphanol covering our clinical dose range Company to host a conference call and webcast today at 5:00 p .m. |
prnewswire.com |
2024-12-03 18:05:00 |
Czytaj oryginał (ang.) |
| Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference |
Corporate presentation will be held on Wednesday, December 4, 2024, at 1:00 p.m. ET NEW HAVEN, Conn. |
prnewswire.com |
2024-11-21 09:30:00 |
Czytaj oryginał (ang.) |
| Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates |
Completed enrollment of the Phase 2a RIVER trial in refractory chronic cough (RCC) with topline results expected in the first quarter of 2025 Reached 50% enrollment for the Phase 2b CORAL trial in chronic cough in idiopathic pulmonary fibrosis (IPF), with sample size re-estimation outcome expected in December 2024 Ended the third quarter of 2024 with $65.5 million in cash, cash equivalents and marketable securities, with expected cash runway into the second half of 2026 Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn. |
prnewswire.com |
2024-11-06 18:05:00 |
Czytaj oryginał (ang.) |
| Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024 |
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn. |
prnewswire.com |
2024-10-30 18:05:00 |
Czytaj oryginał (ang.) |
| Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough |
Topline results are expected in the first quarter of 2025 NEW HAVEN, Conn. , Oct. 21, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that it has completed enrollment in its Phase 2a trial for the treatment of RCC ("RIVER") and expects to report topline data in the first quarter of 2025. |
prnewswire.com |
2024-10-21 11:30:00 |
Czytaj oryginał (ang.) |
| Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences |
NEW HAVEN, Conn. , Oct. 15, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending the following investor and medical conferences in October and November. |
prnewswire.com |
2024-10-15 11:30:00 |
Czytaj oryginał (ang.) |
| Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program |
Phase 2b CORAL trial in idiopathic pulmonary fibrosis (IPF) chronic cough reaches 50% enrollment milestone; sample size re-estimation results expected in December 2024 Human Abuse Potential (HAP) study dosing complete; topline results expected in December 2024 NEW HAVEN, Conn. , Oct. 3, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today provided updates on its clinical development programs. |
prnewswire.com |
2024-10-03 20:05:00 |
Czytaj oryginał (ang.) |
| Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D. |
NEW HAVEN, Conn. , Sept. 30, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the appointment of James V. |
prnewswire.com |
2024-09-30 21:30:00 |
Czytaj oryginał (ang.) |
| Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024 |
Professor Alyn Morice will present an analysis of cough relief in patients with idiopathic pulmonary fibrosis who were treated with nalbuphine ER NEW HAVEN, Conn. , Sept. 26, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that data from the Phase 2a CANAL trial will be presented at CHEST 2024 held in Boston, Massachusetts from October 6-9. |
prnewswire.com |
2024-09-26 11:30:00 |
Czytaj oryginał (ang.) |
| Why Trevi Therapeutics Could Be a Triple-Bagger Biotech Stock |
Publicly traded biopharmaceutical firms can have large, sometimes triple-bagger, expectations placed on them by Wall Street analysts. This is especially true for companies like Trevi Therapeutics NASDAQ: TRVI, which don't yet have any products approved by the Food and Drug Administration (FDA). |
marketbeat.com |
2024-09-06 11:31:49 |
Czytaj oryginał (ang.) |
| Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024 |
Professor Jacky Smith will present on the correlation between the change in objective cough count and improvement in patient-reported outcomes with nalbuphine ER in IPF patients NEW HAVEN, Conn. , Sept. 4, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that data from the Phase 2a CANAL trial will be presented at the European Respiratory Society (ERS) Congress 2024 being held in Vienna, Austria from September 7-11. |
prnewswire.com |
2024-09-04 20:05:00 |
Czytaj oryginał (ang.) |
| Trevi Therapeutics to Participate in September Investor and Medical Conferences |
NEW HAVEN, Conn. , Aug. 28, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending the following investor and medical conferences in September. |
prnewswire.com |
2024-08-28 11:30:00 |
Czytaj oryginał (ang.) |
| Trevi Therapeutics, Inc. (TRVI) Q2 2024 Earnings Call Transcript |
Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Jennifer Good - President and CEO Lisa Delfini - Chief Financial Officer David Clark - Chief Medical Officer Conference Call Participants Thomas Smith - Leerink Partners Leland Gershell - Oppenheimer Mayank Mamtani - B. Riley Securities Brandon Folkes - Rodman & Renshaw John Gionco - Needham & Company Debanjana Chatterjee - JonesTrading Operator Good afternoon. |
seekingalpha.com |
2024-08-11 05:28:06 |
Czytaj oryginał (ang.) |
| Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance |
Topline results expected in the fourth quarter of 2024 in the Phase 2a RIVER trial in refractory chronic cough (RCC) Sample size re-estimation milestone is expected in the fourth quarter of 2024 in the Phase 2b CORAL trial in chronic cough in idiopathic pulmonary fibrosis (IPF) Ended the second quarter of 2024 with $69.5 million in cash, cash equivalents and marketable securities with expected cash runway into 2026 Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn. |
prnewswire.com |
2024-08-08 20:05:00 |
Czytaj oryginał (ang.) |
| Trevi Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 8, 2024 |
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn. |
prnewswire.com |
2024-08-01 11:30:00 |
Czytaj oryginał (ang.) |
| Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events |
Two abstracts accepted for oral presentation at the 13th London International Cough Symposium NEW HAVEN, Conn. , July 2, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending investor and medical conferences in July and August. |
prnewswire.com |
2024-07-02 11:30:00 |
Czytaj oryginał (ang.) |
| Trevi Therapeutics, Inc. (TRVI) Q1 2024 Earnings Call Transcript |
Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Jennifer Good - President and Chief Executive Officer Lisa Delfini - Chief Financial Officer David Clark - Chief Medical Officer Conference Call Participants Leland Gershell - Oppenheimer Jack Padovano - Stifel Nathanael Charoensook - Leerink Partners Mayank Mamtani - B. Riley Securities Operator Good afternoon, and welcome to the Trevi Therapeutics First Quarter 2024 Earnings Conference Call. |
seekingalpha.com |
2024-05-11 17:56:10 |
Czytaj oryginał (ang.) |